Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Does the media favor EBS or JNJ?

In the previous week, Johnson & Johnson had 157 more articles in the media than Emergent Biosolutions. MarketBeat recorded 159 mentions for Johnson & Johnson and 2 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.14 beat Emergent Biosolutions' score of 0.53 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	104 Very Positive mention(s)	12 Positive mention(s)	22 Neutral mention(s)	8 Negative mention(s)	2 Very Negative mention(s)	Positive

Do institutionals & insiders believe in EBS or JNJ?

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts rate EBS or JNJ?

Emergent Biosolutions currently has a consensus price target of $14.33, indicating a potential upside of 106.53%. Johnson & Johnson has a consensus price target of $172.87, indicating a potential upside of 5.63%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Johnson & Johnson	0 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.57

Which has more volatility and risk, EBS or JNJ?

Emergent Biosolutions has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Is EBS or JNJ more profitable?

Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.07% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-13.63%	-0.52%	-0.17%
Johnson & Johnson	25.00%	33.07%	13.16%

Which has higher valuation and earnings, EBS or JNJ?

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$1.04B	0.36	-$190.60M	-$2.71	-2.56
Johnson & Johnson	$88.82B	4.43	$14.07B	$9.35	17.50

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.